Search Market Research Report

Discover Our Latest Reports
Discover Our Featured Reports
Discover Top Selling Reports

Antiviral Drug Resistance Market Size, Share Global Analysis Report, 2020–2026

report img

Antiviral Drug Resistance Market By Product (Instruments and Kits & Reagents), By Disease Indication [Cytomegalovirus (CMV), Human Immunodeficiency Virus (HIV), and Hepatitis], By Technology [Next Generation Sequencing (NGS), Immunodiagnostics, Polymerase Chain Reaction (PCR), and Other Technologies], By End User (Research Institutes, Hospitals & Clinics, and Diagnostic or Pathology Laboratories), And By Region: Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecast 2020–2026

Industry Insights

This specialized and expertise oriented industry research report scrutinizes the technical and commercial business outlook of the global antiviral drug resistance industry. The report analyzes and declares the historical and current trends analysis of the global antiviral drug resistance industry and subsequently recommends the projected trends anticipated to be observed in the global antiviral drug resistance market during the upcoming years.

Global Antiviral Drug Resistance Market Size

To know more about this report | Request Free Sample Copy

The global antiviral drug resistance market report analyzes and notifies the industry statistics at the global as well as regional and country levels in order to acquire a thorough perspective of the entire global antiviral drug resistance market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value (USD Million) from FY 2016 – 2026.

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the global antiviral drug resistance industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Throughout our research report, we have encompassed all the proven models and tools of industry analysis and extensively illustrated all the key business strategies and business models adopted in the global antiviral drug resistance industry. The report provides an all-inclusive and detailed competitive landscape prevalent in the global antiviral drug resistance market.

The report utilizes established industry analysis tools and models such as Porter’s Five Forces framework to analyze and recognize critical business strategies adopted by various stakeholders involved in the entire value chain of the global antiviral drug resistance industry. The global antiviral drug resistance market report additionally employs SWOT analysis and PESTLE analysis models for further in-depth analysis.

The report study further includes an in-depth analysis of industry players' market shares and provides an overview of leading players' market position in the global antiviral drug resistance sector. Key strategic developments in the global antiviral drug resistance market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the global antiviral drug resistance market are appropriately highlighted in the report.

Antiviral drug resistance refers to a decline in the effectiveness of antiviral drugs that inhibit the proliferation of virion within the host cells and eventually eradicate the infectious particles from the host system. Any virus can acquire drug resistance characteristics through particular mutations in the genotype. In some instances, the drugs may completely lose their virus targeting efficiency, which is one of the mounting concerns among the patients with weak immune systems.

The global antiviral drug resistance market research report delivers an acute valuation and taxonomy of the global antiviral drug resistance industry by practically splitting the market on the basis of different SEGMENTS, and regions. Through the analysis of the historical and projected trends, all the segments and sub-segments were evaluated through the bottom-up approach, and different market sizes have been projected for FY 2020 to FY 2026. The regional segmentation of the global antiviral drug resistance industry includes the complete classification of all the major continents including North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Further, country-wise data for the global antiviral drug resistance industry is provided for the leading economies of the world.

The global antiviral drug resistance market is segmented based on the product, disease indication, technology, end-user, and region. The global antiviral drug resistance market is segmented into instruments and kits & reagents, on the basis of product. By disease infection, the global industry is bifurcated into cytomegalovirus (CMV), human immunodeficiency virus (HIV), and hepatitis. Technology-wise, the global market is sectored into next-generation sequencing (NGS), immunodiagnostics, polymerase chain reaction (PCR), and other technologies. The end-user segment divides the market into research institutes, hospitals & clinics, and diagnostic or pathology laboratories.

logoReport Scope

Report Attribute

Details

Market Size in 2019

USD 2,500 Million

Projected Market Size in 2025

USD 4,000 Million

CAGR Growth Rate

6.5% CAGR

Base Year 2019

Forecast Years

2020-2026

Key Market Players

Seimens AG, Bio-Rad Laboratories Inc., Abbott, Trinity Biotech, ACON Laboratories Inc., F. Hoffmann-La Roche Ltd., AccuBioTech Co. Ltd., Danaher, and BioMérieux SA, among others.

Key Segment

By Product, By Disease Indication, By Technology, By End-User, By Region

Major Regions Covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Purchase Options

Request customized purchase options to meet your research needs. Explore purchase options

The taxonomy of the global antiviral drug resistance industry by its scope and segmentation is as follows:

logoSome of the essential players operating in the global antiviral drug resistance market, but not restricted to include

  • Seimens AG
  • Bio-Rad Laboratories Inc.
  • Abbott
  • Trinity Biotech
  • ACON Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • AccuBioTech Co. Ltd.
  • Danaher
  • BioMérieux SA
  • among others.

logo Product Segmentation Analysis

  • Instruments
  • Kits and Reagents

logo Disease Indication Segmentation Analysis

  • Cytomegalovirus (CMV)
  • Human Immunodeficiency Virus (HIV)
  • Hepatitis

logo Technology Segmentation Analysis

  • Next-Generation Sequencing (NGS)
  • Immunodiagnostics
  • Polymerase Chain Reaction (PCR)
  • Other Technologies

logo End-User Segmentation Analysis

  • Research Institutes
  • Hospitals & Clinics
  • Diagnostic or Pathology Laboratories

logo Regional Segmentation Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • The UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

  1. CHAPTER 1. Executive Summary
  2. CHAPTER 2. Antiviral Drug Resistance market – Product Analysis
    1. 2.1. Global Antiviral Drug Resistance Market – Product Overview
    2. 2.2. Global Antiviral Drug Resistance Market Share, by Product, 2018 & 2025 (USD Million)
    3. 2.3. Instruments
      1. 2.3.1. Global Instruments Antiviral Drug Resistance Market, 2016-2026 (USD Million)
    4. 2.4. Kits and Reagents
      1. 2.4.1. Global Kits and Reagents Antiviral Drug Resistance Market, 2016-2026 (USD Million)
  3. CHAPTER 3. Antiviral Drug Resistance market – Disease Indication Analysis
    1. 3.1. Global Antiviral Drug Resistance Market – Disease Indication Overview
    2. 3.2. Global Antiviral Drug Resistance Market Share, by Disease Indication, 2018 & 2025 (USD Million)
    3. 3.3. Cytomegalovirus (CMV)
      1. 3.3.1. Global Cytomegalovirus (CMV) Antiviral Drug Resistance Market, 2016-2026 (USD Million)
    4. 3.4. Human Immunodeficiency Virus (HIV)
      1. 3.4.1. Global Human Immunodeficiency Virus (HIV) Antiviral Drug Resistance Market, 2016-2026 (USD Million)
    5. 3.5. Hepatitis
      1. 3.5.1. Global Hepatitis Antiviral Drug Resistance Market, 2016-2026 (USD Million)
  4. CHAPTER 4. Antiviral Drug Resistance market – Technology Analysis
    1. 4.1. Global Antiviral Drug Resistance Market – Technology Overview
    2. 4.2. Global Antiviral Drug Resistance Market Share, by Technology, 2018 & 2025 (USD Million)
    3. 4.3. Next-Generation Sequencing (NGS)
      1. 4.3.1. Global Next-Generation Sequencing (NGS) Antiviral Drug Resistance Market, 2016-2026 (USD Million)
    4. 4.4. Immunodiagnostics
      1. 4.4.1. Global Immunodiagnostics Antiviral Drug Resistance Market, 2016-2026 (USD Million)
    5. 4.5. Polymerase Chain Reaction (PCR)
      1. 4.5.1. Global Polymerase Chain Reaction (PCR) Antiviral Drug Resistance Market, 2016-2026 (USD Million)
    6. 4.6. Other Technologies
      1. 4.6.1. Global Other Technologies Antiviral Drug Resistance Market, 2016-2026 (USD Million)
  5. CHAPTER 5. Antiviral Drug Resistance market – End-User Analysis
    1. 5.1. Global Antiviral Drug Resistance Market – End-User Overview
    2. 5.2. Global Antiviral Drug Resistance Market Share, by End-User, 2018 & 2025 (USD Million)
    3. 5.3. Research Institutes
      1. 5.3.1. Global Research Institutes Antiviral Drug Resistance Market, 2016-2026 (USD Million)
    4. 5.4. Hospitals & Clinics
      1. 5.4.1. Global Hospitals & Clinics Antiviral Drug Resistance Market, 2016-2026 (USD Million)
    5. 5.5. Diagnostic or Pathology Laboratories
      1. 5.5.1. Global Diagnostic or Pathology Laboratories Antiviral Drug Resistance Market, 2016-2026 (USD Million)
  6. CHAPTER 6. Antiviral Drug Resistance market – Regional Analysis
    1. 6.1. Global Antiviral Drug Resistance Market Regional Overview
    2. 6.2. Global Antiviral Drug Resistance Market Share, by Region, 2018 & 2025 (Value)
    3. 6.3. North America
      1. 6.3.1. North America Antiviral Drug Resistance Market size and forecast, 2016-2026
      2. 6.3.2. North America Antiviral Drug Resistance Market, by Country, 2018 & 2025 (USD Million)
      3. 6.3.3. North America Antiviral Drug Resistance Market, by Product, 2016-2026
        1. 6.3.3.1. North America Antiviral Drug Resistance Market, by Product, 2016-2026 (USD Million)
      4. 6.3.4. North America Antiviral Drug Resistance Market, by Disease Indication, 2016-2026
        1. 6.3.4.1. North America Antiviral Drug Resistance Market, by Disease Indication, 2016-2026 (USD Million)
      5. 6.3.5. North America Antiviral Drug Resistance Market, by Technology, 2016-2026
        1. 6.3.5.1. North America Antiviral Drug Resistance Market, by Technology, 2016-2026 (USD Million)
      6. 6.3.6. North America Antiviral Drug Resistance Market, by End-User, 2016-2026
        1. 6.3.6.1. North America Antiviral Drug Resistance Market, by End-User, 2016-2026 (USD Million)
      7. 6.3.7. U.S.
        1. 6.3.7.1. U.S. Market size and forecast, 2016-2026 (USD Million)
      8. 6.3.8. Canada
        1. 6.3.8.1. Canada Market size and forecast, 2016-2026 (USD Million)
    4. 6.4. Europe
      1. 6.4.1. Europe Antiviral Drug Resistance Market size and forecast, 2016-2026
      2. 6.4.2. Europe Antiviral Drug Resistance Market, by Country, 2018 & 2025 (USD Million)
      3. 6.4.3. Europe Antiviral Drug Resistance Market, by Product, 2016-2026
        1. 6.4.3.1. Europe Antiviral Drug Resistance Market, by Product, 2016-2026 (USD Million)
      4. 6.4.4. Europe Antiviral Drug Resistance Market, by Disease Indication, 2016-2026
        1. 6.4.4.1. Europe Antiviral Drug Resistance Market, by Disease Indication, 2016-2026 (USD Million)
      5. 6.4.5. Europe Antiviral Drug Resistance Market, by Technology, 2016-2026
        1. 6.4.5.1. Europe Antiviral Drug Resistance Market, by Technology, 2016-2026 (USD Million)
      6. 6.4.6. Europe Antiviral Drug Resistance Market, by End-User, 2016-2026
        1. 6.4.6.1. Europe Antiviral Drug Resistance Market, by End-User, 2016-2026 (USD Million)
      7. 6.4.7. Germany
        1. 6.4.7.1. Germany Market size and forecast, 2016-2026 (USD Million)
      8. 6.4.8. France
        1. 6.4.8.1. France Market size and forecast, 2016-2026 (USD Million)
      9. 6.4.9. U.K.
        1. 6.4.9.1. U.K. Market size and forecast, 2016-2026 (USD Million)
      10. 6.4.10. Italy
        1. 6.4.10.1. Italy Market size and forecast, 2016-2026 (USD Million)
      11. 6.4.11. Spain
        1. 6.4.11.1. Spain Market size and forecast, 2016-2026 (USD Million)
      12. 6.4.12. Rest of Europe
        1. 6.4.12.1. Rest of Europe Market size and forecast, 2016-2026 (USD Million)
    5. 6.5. Asia Pacific
      1. 6.5.1. Asia Pacific Antiviral Drug Resistance Market size and forecast, 2016-2026
      2. 6.5.2. Asia Pacific Antiviral Drug Resistance Market, by Country, 2018 & 2025 (USD Million)
      3. 6.5.3. Asia Pacific Antiviral Drug Resistance Market, by Product, 2016-2026
        1. 6.5.3.1. Asia Pacific Antiviral Drug Resistance Market, by Product, 2016-2026 (USD Million)
      4. 6.5.4. Asia Pacific Antiviral Drug Resistance Market, by Disease Indication, 2016-2026
        1. 6.5.4.1. Asia Pacific Antiviral Drug Resistance Market, by Disease Indication, 2016-2026 (USD Million)
      5. 6.5.5. Asia Pacific Antiviral Drug Resistance Market, by Technology, 2016-2026
        1. 6.5.5.1. Asia Pacific Antiviral Drug Resistance Market, by Technology, 2016-2026 (USD Million)
      6. 6.5.6. Asia Pacific Antiviral Drug Resistance Market, by End-User, 2016-2026
        1. 6.5.6.1. Asia Pacific Antiviral Drug Resistance Market, by End-User, 2016-2026 (USD Million)
      7. 6.5.7. China
        1. 6.5.7.1. China Market size and forecast, 2016-2026 (USD Million)
      8. 6.5.8. Japan
        1. 6.5.8.1. Japan Market size and forecast, 2016-2026 (USD Million)
      9. 6.5.9. India
        1. 6.5.9.1. India Market size and forecast, 2016-2026 (USD Million)
      10. 6.5.10. South Korea
        1. 6.5.10.1. South Korea Market size and forecast, 2016-2026 (USD Million)
      11. 6.5.11. South-East Asia
        1. 6.5.11.1. South-East Asia Market size and forecast, 2016-2026 (USD Million)
      12. 6.5.12. Rest of Asia Pacific
        1. 6.5.12.1. Rest of Asia Pacific Market size and forecast, 2016-2026 (USD Million)
    6. 6.6. Latin America
      1. 6.6.1. Latin America Antiviral Drug Resistance Market size and forecast, 2016-2026
      2. 6.6.2. Latin America Antiviral Drug Resistance Market, by Country, 2018 & 2025 (USD Million)
      3. 6.6.3. Latin America Antiviral Drug Resistance Market, by Product, 2016-2026
        1. 6.6.3.1. Latin America Antiviral Drug Resistance Market, by Product, 2016-2026 (USD Million)
      4. 6.6.4. Latin America Antiviral Drug Resistance Market, by Disease Indication, 2016-2026
        1. 6.6.4.1. Latin America Antiviral Drug Resistance Market, by Disease Indication, 2016-2026 (USD Million)
      5. 6.6.5. Latin America Antiviral Drug Resistance Market, by Technology, 2016-2026
        1. 6.6.5.1. Latin America Antiviral Drug Resistance Market, by Technology, 2016-2026 (USD Million)
      6. 6.6.6. Latin America Antiviral Drug Resistance Market, by End-User, 2016-2026
        1. 6.6.6.1. Latin America Antiviral Drug Resistance Market, by End-User, 2016-2026 (USD Million)
      7. 6.6.7. Brazil
        1. 6.6.7.1. Brazil Market size and forecast, 2016-2026 (USD Million)
      8. 6.6.8. Mexico
        1. 6.6.8.1. Mexico Market size and forecast, 2016-2026 (USD Million)
      9. 6.6.9. Rest of Latin America
        1. 6.6.9.1. Rest of Latin America Market size and forecast, 2016-2026 (USD Million)
    7. 6.7. The Middle-East and Africa
      1. 6.7.1. The Middle-East and Africa Antiviral Drug Resistance Market size and forecast, 2016-2026
      2. 6.7.2. The Middle-East and Africa Antiviral Drug Resistance Market, by Country, 2018 & 2025 (USD Million)
      3. 6.7.3. The Middle-East and Africa Antiviral Drug Resistance Market, by Product, 2016-2026
        1. 6.7.3.1. The Middle-East and Africa Antiviral Drug Resistance Market, by Product, 2016-2026 (USD Million)
      4. 6.7.4. The Middle-East and Africa Antiviral Drug Resistance Market, by Disease Indication, 2016-2026
        1. 6.7.4.1. The Middle-East and Africa Antiviral Drug Resistance Market, by Disease Indication, 2016-2026 (USD Million)
      5. 6.7.5. The Middle-East and Africa Antiviral Drug Resistance Market, by Technology, 2016-2026
        1. 6.7.5.1. The Middle-East and Africa Antiviral Drug Resistance Market, by Technology, 2016-2026 (USD Million)
      6. 6.7.6. The Middle-East and Africa Antiviral Drug Resistance Market, by End-User, 2016-2026
        1. 6.7.6.1. The Middle-East and Africa Antiviral Drug Resistance Market, by End-User, 2016-2026 (USD Million)
      7. 6.7.7. GCC Countries
        1. 6.7.7.1. GCC Countries Market size and forecast, 2016-2026 (USD Million)
      8. 6.7.8. South Africa
        1. 6.7.8.1. South Africa Market size and forecast, 2016-2026 (USD Million)
      9. 6.7.9. Rest of Middle-East Africa
        1. 6.7.9.1. Rest of Middle-East Africa Market size and forecast, 2016-2026 (USD Million)
  7. CHAPTER 7. Antiviral Drug Resistance market – Competitive Landscape
    1. 7.1. Competitor Market Share – Revenue
    2. 7.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players
    3. 7.3. Strategic Development
      1. 7.3.1. Acquisitions and Mergers
      2. 7.3.2. New Products
      3. 7.3.3. Research & Development Activities
  8. CHAPTER 8. Company Profiles
    1. 8.1. Seimens AG
      1. 8.1.1. Company Overview
      2. 8.1.2. Seimens AG Revenue and Gross Margin
      3. 8.1.3. Product portfolio
      4. 8.1.4. Recent initiatives
    2. 8.2. Bio-Rad Laboratories Inc.
      1. 8.2.1. Company Overview
      2. 8.2.2. Bio-Rad Laboratories Inc. Revenue and Gross Margin
      3. 8.2.3. Product portfolio
      4. 8.2.4. Recent initiatives
    3. 8.3. Abbott
      1. 8.3.1. Company Overview
      2. 8.3.2. Abbott Revenue and Gross Margin
      3. 8.3.3. Product portfolio
      4. 8.3.4. Recent initiatives
    4. 8.4. Trinity Biotech
      1. 8.4.1. Company Overview
      2. 8.4.2. Trinity Biotech Revenue and Gross Margin
      3. 8.4.3. Product portfolio
      4. 8.4.4. Recent initiatives
    5. 8.5. ACON Laboratories Inc.
      1. 8.5.1. Company Overview
      2. 8.5.2. ACON Laboratories Inc. Revenue and Gross Margin
      3. 8.5.3. Product portfolio
      4. 8.5.4. Recent initiatives
    6. 8.6. F. Hoffmann-La Roche Ltd.
      1. 8.6.1. Company Overview
      2. 8.6.2. F. Hoffmann-La Roche Ltd. Revenue and Gross Margin
      3. 8.6.3. Product portfolio
      4. 8.6.4. Recent initiatives
    7. 8.7. AccuBioTech Co. Ltd.
      1. 8.7.1. Company Overview
      2. 8.7.2. AccuBioTech Co. Ltd. Revenue and Gross Margin
      3. 8.7.3. Product portfolio
      4. 8.7.4. Recent initiatives
    8. 8.8. Danaher
      1. 8.8.1. Company Overview
      2. 8.8.2. Danaher Revenue and Gross Margin
      3. 8.8.3. Product portfolio
      4. 8.8.4. Recent initiatives
    9. 8.9. BioMérieux SA
      1. 8.9.1. Company Overview
      2. 8.9.2. BioMérieux SA Revenue and Gross Margin
      3. 8.9.3. Product portfolio
      4. 8.9.4. Recent initiatives
  9. CHAPTER 9. Antiviral Drug Resistance — Industry Analysis
    1. 9.1. Antiviral Drug Resistance Market – Key Trends
      1. 9.1.1. Market Drivers
      2. 9.1.2. Market Restraints
      3. 9.1.3. Market Opportunities
    2. 9.2. Value Chain Analysis
    3. 9.3. Technology Roadmap and Timeline
    4. 9.4. Antiviral Drug Resistance Market – Attractiveness Analysis
      1. 9.4.1. By Product
      2. 9.4.2. By Disease Indication
      3. 9.4.3. By Technology
      4. 9.4.4. By End-User
      5. 9.4.5. By Region
  10. CHAPTER 10. Marketing Strategy Analysis, Distributors
    1. 10.1. Marketing Channel
    2. 10.2. Direct Marketing
    3. 10.3. Indirect Marketing
    4. 10.4. Marketing Channel Development Trend
    5. 10.5. Economic/Political Environmental Change
  11. CHAPTER 11. Report Conclusion
  12. CHAPTER 12. Research Approach & Methodology
    1. 12.1. Report Description
    2. 12.2. Research Scope
    3. 12.3. Research Methodology
      1. 12.3.1. Secondary Research
      2. 12.3.2. Primary Research
      3. 12.3.3. Models
        1. 12.3.3.1. Company Share Analysis Model
        2. 12.3.3.2. Revenue Based Modeling
        3. 12.3.3.3. Research Limitations

        List of Figures

        FIG. 1 Global Antiviral Drug Resistance Market, 2016-2026 (USD Million)
        FIG. 2 Global Antiviral Drug Resistance Market Share, by Product, 2018 & 2025 (USD Million)
        FIG. 3 Global Instruments Antiviral Drug Resistance Market, 2016-2026 (USD Million)
        FIG. 4 Global Kits and Reagents Antiviral Drug Resistance Market, 2016-2026 (USD Million)
        FIG. 5 Global Antiviral Drug Resistance Market Share, by Disease Indication, 2018 & 2025 (USD Million)
        FIG. 6 Global Cytomegalovirus (CMV) Antiviral Drug Resistance Market, 2016-2026 (USD Million)
        FIG. 7 Global Human Immunodeficiency Virus (HIV) Antiviral Drug Resistance Market, 2016-2026 (USD Million)
        FIG. 8 Global Hepatitis Antiviral Drug Resistance Market, 2016-2026 (USD Million)
        FIG. 9 Global Antiviral Drug Resistance Market Share, by Technology, 2018 & 2025 (USD Million)
        FIG. 10 Global Next-Generation Sequencing (NGS) Antiviral Drug Resistance Market, 2016-2026 (USD Million)
        FIG. 11 Global Immunodiagnostics Antiviral Drug Resistance Market, 2016-2026 (USD Million)
        FIG. 12 Global Polymerase Chain Reaction (PCR) Antiviral Drug Resistance Market, 2016-2026 (USD Million)
        FIG. 13 Global Other Technologies Antiviral Drug Resistance Market, 2016-2026 (USD Million)
        FIG. 14 Global Antiviral Drug Resistance Market Share, by End-User, 2018 & 2025 (USD Million)
        FIG. 15 Global Research Institutes Antiviral Drug Resistance Market, 2016-2026 (USD Million)
        FIG. 16 Global Hospitals & Clinics Antiviral Drug Resistance Market, 2016-2026 (USD Million)
        FIG. 17 Global Diagnostic or Pathology Laboratories Antiviral Drug Resistance Market, 2016-2026 (USD Million)
        FIG. 18 Global Antiviral Drug Resistance Market Share, by Region, 2018 & 2025
        FIG. 19 North America Antiviral Drug Resistance Market, 2016-2026
        FIG. 20 U.S. Antiviral Drug Resistance Market, 2016-2026
        FIG. 21 Canada Antiviral Drug Resistance Market, 2016-2026
        FIG. 22 Europe Antiviral Drug Resistance Market, 2016-2026
        FIG. 23 Germany Antiviral Drug Resistance Market, 2016-2026
        FIG. 24 France Antiviral Drug Resistance Market, 2016-2026
        FIG. 25 U.K. Antiviral Drug Resistance Market, 2016-2026
        FIG. 26 Italy Antiviral Drug Resistance Market, 2016-2026
        FIG. 27 Spain Antiviral Drug Resistance Market, 2016-2026
        FIG. 28 Rest of Europe Antiviral Drug Resistance Market, 2016-2026
        FIG. 29 Asia Pacific Antiviral Drug Resistance Market, 2016-2026
        FIG. 30 China Antiviral Drug Resistance Market, 2016-2026
        FIG. 31 Japan Antiviral Drug Resistance Market, 2016-2026
        FIG. 32 India Antiviral Drug Resistance Market, 2016-2026
        FIG. 33 South  Korea Antiviral Drug Resistance Market, 2016-2026
        FIG. 34 South-East Asia Antiviral Drug Resistance Market, 2016-2026
        FIG. 35 Rest of Asia Pacific Antiviral Drug Resistance Market, 2016-2026
        FIG. 36 Latin America Antiviral Drug Resistance Market, 2016-2026
        FIG. 37 Brazil Antiviral Drug Resistance Market, 2016-2026
        FIG. 38 Mexico Antiviral Drug Resistance Market, 2016-2026
        FIG. 39 Rest of Latin America Antiviral Drug Resistance Market, 2016-2026
        FIG. 40 The Middle-East and Africa Antiviral Drug Resistance Market, 2016-2026
        FIG. 41 GCC Countries Antiviral Drug Resistance Market, 2016-2026
        FIG. 42 South Africa Antiviral Drug Resistance Market, 2016-2026
        FIG. 43 Rest of Middle-East Africa Antiviral Drug Resistance Market, 2016-2026
        FIG. 44 Competitor Market Share – Revenue
        FIG. 45 Seimens AG Revenue and Growth Rate
        FIG. 46 Seimens AG Market Share
        FIG. 47 Bio-Rad Laboratories Inc. Revenue and Growth Rate
        FIG. 48 Bio-Rad Laboratories Inc. Market Share
        FIG. 49 Abbott Revenue and Growth Rate
        FIG. 50 Abbott Market Share
        FIG. 51 Trinity Biotech Revenue and Growth Rate
        FIG. 52 Trinity Biotech Market Share
        FIG. 53 ACON Laboratories Inc. Revenue and Growth Rate
        FIG. 54 ACON Laboratories Inc. Market Share
        FIG. 55 F. Hoffmann-La Roche Ltd. Revenue and Growth Rate
        FIG. 56 F. Hoffmann-La Roche Ltd. Market Share
        FIG. 57 AccuBioTech Co. Ltd. Revenue and Growth Rate
        FIG. 58 AccuBioTech Co. Ltd. Market Share
        FIG. 59 Danaher Revenue and Growth Rate
        FIG. 60 Danaher Market Share
        FIG. 61 BioMérieux SA Revenue and Growth Rate
        FIG. 62 BioMérieux SA Market Share
        FIG. 63 Market Dynamics
        FIG. 64 Global Antiviral Drug Resistance – Value Chain Analysis
        FIG. 65 Technology Roadmap and Timeline
        FIG. 66 Market Attractiveness Analysis – By Product
        FIG. 67 Market Attractiveness Analysis – By Disease Indication
        FIG. 68 Market Attractiveness Analysis – By Technology
        FIG. 69 Market Attractiveness Analysis – By End-User
        FIG. 70 Market Attractiveness Analysis – By Region
        FIG. 71 Market Channel
        FIG. 72 Marketing Channel Development Trend
        FIG. 73 Growth in World Gross Product, 2008-2018
        

        List of Tables

        TABLE 1 Global Antiviral Drug Resistance Market, 2018 & 2025 (USD Million)
        TABLE 2 Global Antiviral Drug Resistance market, by Product, 2016-2026 (USD Million)
        TABLE 3 Global Antiviral Drug Resistance market, by Disease Indication, 2016-2026 (USD Million)
        TABLE 4 Global Antiviral Drug Resistance market, by Technology, 2016-2026 (USD Million)
        TABLE 5 Global Antiviral Drug Resistance market, by End-User, 2016-2026 (USD Million)
        TABLE 6 Global Antiviral Drug Resistance market, by Region, 2016-2026 (USD Million)
        TABLE 7 North America Antiviral Drug Resistance Market, by Product, 2016-2026 (USD Million)
        TABLE 8 North America Antiviral Drug Resistance Market, by Disease Indication, 2016-2026 (USD Million)
        TABLE 9 North America Antiviral Drug Resistance Market, by Technology, 2016-2026 (USD Million)
        TABLE 10 North America Antiviral Drug Resistance Market, by End-User, 2016-2026 (USD Million)
        TABLE 11 Europe Antiviral Drug Resistance Market, by Product, 2016-2026 (USD Million)
        TABLE 12 Europe Antiviral Drug Resistance Market, by Disease Indication, 2016-2026 (USD Million)
        TABLE 13 Europe Antiviral Drug Resistance Market, by Technology, 2016-2026 (USD Million)
        TABLE 14 Europe Antiviral Drug Resistance Market, by End-User, 2016-2026 (USD Million)
        TABLE 15 Asia Pacific Antiviral Drug Resistance Market, by Product, 2016-2026 (USD Million)
        TABLE 16 Asia Pacific Antiviral Drug Resistance Market, by Disease Indication, 2016-2026 (USD Million)
        TABLE 17 Asia Pacific Antiviral Drug Resistance Market, by Technology, 2016-2026 (USD Million)
        TABLE 18 Asia Pacific Antiviral Drug Resistance Market, by End-User, 2016-2026 (USD Million)
        TABLE 19 Latin America Antiviral Drug Resistance Market, by Product, 2016-2026 (USD Million)
        TABLE 20 Latin America Antiviral Drug Resistance Market, by Disease Indication, 2016-2026 (USD Million)
        TABLE 21 Latin America Antiviral Drug Resistance Market, by Technology, 2016-2026 (USD Million)
        TABLE 22 Latin America Antiviral Drug Resistance Market, by End-User, 2016-2026 (USD Million)
        TABLE 23 The Middle-East and Africa Antiviral Drug Resistance Market, by Product, 2016-2026 (USD Million)
        TABLE 24 The Middle-East and Africa Antiviral Drug Resistance Market, by Disease Indication, 2016-2026 (USD Million)
        TABLE 25 The Middle-East and Africa Antiviral Drug Resistance Market, by Technology, 2016-2026 (USD Million)
        TABLE 26 The Middle-East and Africa Antiviral Drug Resistance Market, by End-User, 2016-2026 (USD Million)
        TABLE 27 Global Antiviral Drug Resistance Market - Company Revenue Analysis 2016-2019 (USD Million)
        TABLE 28 Global Antiviral Drug Resistance Market - Company Revenue Share Analysis 2016-2019(%)
        TABLE 29 Acquisitions and Mergers
        TABLE 30 New Product/Service Launch
        TABLE 31 Research & Development Activities
        TABLE 32 Market Drivers
        TABLE 33 Market Restraints
        TABLE 34 Market Opportunities
        

Industry Major Market Players

  •  Seimens AG
  •  Bio-Rad Laboratories Inc.
  •  Abbott
  •  Trinity Biotech
  •  ACON Laboratories Inc.
  •  F. Hoffmann-La Roche Ltd.
  •  AccuBioTech Co. Ltd.
  •  Danaher
  •  BioMérieux SA